Update date
31 Dec 2024
Shareable Research Card
This metric view shows ONCY - ONCOLYTICS BIOTECH INC equity history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest reported equity: CA$5,983,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Update date
31 Dec 2024
Page type
Metric history
Latest period
Q4 2024
SEC-backed company facts were refreshed from filings filed on 12 Aug 2026.
Benchmark Context
ONCOLYTICS BIOTECH INC sits in the lower half of the current equity sample.
Compared with
Compared with 9 companies reporting equity in CAD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0.4x the current sample midpoint. Equity is down about 78% versus the comparable prior period.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Latest period: Q4 2024. Period end: 31 Dec 2024. Units: CAD. Frequency: quarterly.
Equity is reported in company XBRL facts filed with the SEC.
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare latest available Equity levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
ONCOLYTICS BIOTECH INC appears at rank #6 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | Cronos Group Inc. (cron) | CA$211,640,000 | Instant - 31 Dec 2018 | Open Cronos Group Inc. Equity |
| 2 | Foremost Clean Energy Ltd. (fmst) | CA$24,492,262 | Instant - 31 Mar 2025 | Open Foremost Clean Energy Ltd. Equity |
| 3 | Profound Medical Corp. (prof) | CA$18,664,000 | Instant - 31 Dec 2019 | Open Profound Medical Corp. Equity |
| 4 | MindWalk Holdings Corp. (hyft) | CA$14,860,000 | Instant - 31 Jan 2026 | Open MindWalk Holdings Corp. Equity |
| 5 | Grace Therapeutics, Inc. (grce) | CA$13,962,000 | Instant - 31 Mar 2019 | Open Grace Therapeutics, Inc. Equity |
| 6 | ONCOLYTICS BIOTECH INC (oncy) | CA$5,983,000 | Instant - 31 Dec 2024 | Open ONCOLYTICS BIOTECH INC Equity |
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2024 | CA$5,983,000 | -CA$21,580,000 | -78% | 31 Dec 2024 | 20-F | 07 Mar 2025 | 2024 | FY |
| Q4 2023 | CA$27,563,000 | +CA$1,061,000 | +4% | 31 Dec 2023 | 20-F | 07 Mar 2025 | 2024 | FY |
| Q4 2022 | CA$26,502,000 | -CA$9,597,000 | -27% | 31 Dec 2022 | 20-F | 07 Mar 2025 | 2024 | FY |
| Q4 2021 | CA$36,099,000 | +CA$11,347,000 | +46% | 31 Dec 2021 | 20-F | 07 Mar 2025 | 2024 | FY |
| Q4 2020 | CA$24,752,000 | +CA$24,860,000 | 31 Dec 2020 | 20-F | 12 Mar 2024 | 2023 | FY | |
| Q4 2019 | CA$108,000 | -CA$6,303,363 | -102% | 31 Dec 2019 | 20-F | 03 Mar 2023 | 2022 | FY |
| Q4 2018 | CA$6,195,363 | -CA$2,088,483 | -25% | 31 Dec 2018 | 20-F | 03 Mar 2022 | 2021 | FY |
| Q4 2017 | CA$8,283,846 | -CA$2,405,774 | -23% | 31 Dec 2017 | 20-F | 05 Mar 2021 | 2020 | FY |
| Q4 2016 | CA$10,689,620 | 31 Dec 2016 | 20-F | 06 Mar 2020 | 2019 | FY |